Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis. - Nikolaou A; Ambavane A; Shah A; Ma W; Tosh J; Kapetanakis V; Willson J; Wang F; Hogea C; Gorsh B; Gutierrez B; Sapra S; et al. (Expert review of hematology, 2021)